Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2003-11-05
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Registration Number
- NCT00005962
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Hahnemann University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸CCOP - Columbus, Columbus, Ohio, United States
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Previously Untreated Aggressive Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2003-11-05
- Last Posted Date
- 2016-07-13
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 59
- Registration Number
- NCT00005964
- Locations
- 🇺🇸
Veterans Affairs Medical Center - Columbia (Truman Memorial), Columbia, Missouri, United States
🇺🇸Ellis Fischel Cancer Center - Columbia, Columbia, Missouri, United States
🇺🇸State University of New York - Upstate Medical University, Syracuse, New York, United States
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- Interventions
- Biological: filgrastimBiological: rituximabDrug: CHOP regimenDrug: cyclophosphamideDrug: doxorubicin hydrochlorideDrug: prednisoneDrug: vincristine sulfate
- First Posted Date
- 2003-10-28
- Last Posted Date
- 2013-02-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 120
- Registration Number
- NCT00003595
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸San Francisco General Hospital Medical Center, San Francisco, California, United States
Peripheral Stem Cell Transplantation Followed By Infusion of White Blood Cells in Treating Patients With AIDS-Related Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2003-10-21
- Last Posted Date
- 2016-02-03
- Lead Sponsor
- AIDS Malignancy Consortium
- Registration Number
- NCT00024128
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma
- Conditions
- Neuroblastoma
- Interventions
- Biological: filgrastimBiological: sargramostimDrug: carboplatinDrug: cisplatinDrug: cyclophosphamideDrug: doxorubicin hydrochlorideDrug: etoposideDrug: etoposide phosphateDrug: ifosfamideDrug: isotretinoinDrug: melphalanDrug: thiotepaDrug: vincristine sulfateProcedure: conventional surgeryProcedure: peripheral blood stem cell transplantationRadiation: radiation therapy
- First Posted Date
- 2003-10-09
- Last Posted Date
- 2014-02-13
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 42
- Registration Number
- NCT00017368
- Locations
- 🇺🇸
CCOP - Columbia River Oncology Program, Portland, Oregon, United States
🇺🇸Floating Hospital for Children, Boston, Massachusetts, United States
🇺🇸CCOP - Marshfield Clinic Research Foundation, Marshfield, Wisconsin, United States
Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
- Conditions
- Lymphoma
- First Posted Date
- 2003-10-08
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Registration Number
- NCT00005998
Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2014-01-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00070447
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Hahnemann University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸CCOP - Columbus, Columbus, Ohio, United States
Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2009-04-07
- Lead Sponsor
- British Columbia Cancer Agency
- Registration Number
- NCT00070083
- Locations
- 🇨🇦
British Columbia Cancer Agency - Centre for the Southern Interior, Kelowna, British Columbia, Canada
🇨🇦British Columbia Cancer Agency - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇺🇸Stanford Cancer Center at Stanford University Medical Center, Stanford, California, United States
Radiolabeled Monoclonal Antibody, Cyclophosphamide, and Total Body Irradiation Followed By Donor Stem Cell Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2010-08-24
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT00003868
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy
- Conditions
- Leukemia
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2014-02-20
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 350
- Registration Number
- NCT00070174
- Locations
- 🇺🇸
Loma Linda University Cancer Institute at Loma Linda University Medical Center, Loma Linda, California, United States
🇺🇸St. Barnabas Medical Center, Livingston, New Jersey, United States
🇺🇸All Children's Hospital, St. Petersburg, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.